p.98 抽出テキスト

818. Massel DR, Little SH. Antiplatelet and anticoagulation for patients with prosthetic heart valves. Cochrane Database Syst Rev 2013;2013:CD003464. https://doi.org/10. 1002/14651858.CD003464.pub2 819. Torella M, Torella D, Chiodini P, Franciulli M, Romano G, De Santo L, et al. LOWERing the INtensity of oral anticoaGulant therapy in patients with bileaflet mechanical aortic valve replacement: results from the “LOWERING-IT” Trial. Am Heart J 2010;160: 171–8. https://doi.org/10.1016/j.ahj.2010.05.005 820. Connolly SJ, Pogue J, Eikelboom J, Flaker G, Commerford P, Franzosi MG, et al. Benefit of oral anticoagulant over antiplatelet therapy in atrial fibrillation depends on the quality of international normalized ratio control achieved by centers and countries as measured by time in therapeutic range. Circulation 2008;118:2029–37. https://doi.org/10. 1161/CIRCULATIONAHA.107.750000 821. Eikelboom JW, Connolly SJ, Brueckmann M, Granger CB, Kappetein AP, Mack MJ, et al. Dabigatran versus warfarin in patients with mechanical heart valves. N Engl J Med 2013; 369:1206–14. https://doi.org/10.1056/NEJMoa1300615 822. Puskas JD, Gerdisch M, Nichols D, Fermin L, Rhenman B, Kapoor D, et al. Anticoagulation and antiplatelet strategies after On-X mechanical aortic valve replacement. J Am Coll Cardiol 2018;71:2717–26. https://doi.org/10.1016/j.jacc.2018.03.535 823. Schlitt A, von Bardeleben RS, Ehrlich A, Eimermacher A, Peetz D, Dahm M, et al. Clopidogrel and aspirin in the prevention of thromboembolic complications after mechanical aortic valve replacement (CAPTA). Thromb Res 2003;109:131–35. https://doi.org/10.1016/s0049-3848(03)00143-9 824. Wang TY, Svensson LG, Wen J, Vekstein A, Gerdisch M, Rao VU, et al. Apixaban or warfarin in patients with an On-X mechanical aortic valve. NEJM Evid 2023;2: EVIDoa2300067. https://doi.org/10.1056/EVIDoa2300067 825. Wang M, Zeraatkar D, Obeda M, Lee M, Garcia C, Nguyen L, et al. Drug–drug interactions with warfarin: a systematic review and meta-analysis. Br J Clin Pharmacol 2021; 87:4051–100. https://doi.org/10.1111/bcp.14833 826. Tan CSS, Lee SWH. Warfarin and food, herbal or dietary supplement interactions: a systematic review. Br J Clin Pharmacol 2021;87:352–74. https://doi.org/10.1111/bcp. 14404 827. Heneghan CJ, Garcia-Alamino JM, Spencer EA, Ward AM, Perera R, Bankhead C, et al. Self-monitoring and self-management of oral anticoagulation. Cochrane Database Syst Rev 2016;7:CD003839. https://doi.org/10.1002/14651858.CD003839.pub3 828. Khouja C, Brunton G, Richardson M, Stokes G, Blanchard L, Burchett H, et al. Oral anticoagulants: a systematic overview of reviews on efficacy and safety, genotyping, self-monitoring, and stakeholder experiences. Syst Rev 2022;11:232. https://doi.org/ 10.1186/s13643-022-02098-w 829. Park YK, Lee MJ, Kim JH, Lee JS, Park RW, Kim GM, et al. Genetic and non-genetic factors affecting the quality of anticoagulation control and vascular events in atrial fibrillation. J Stroke Cerebrovasc Dis 2017;26:1383–90. https://doi.org/10.1016/j. jstrokecerebrovasdis.2017.02.022 830. Praxedes MFDS, Silva JLPD, Cruz AJAD, Viana CC, Barbosa HC, Guimaraes NS, et al. Assessment of the relationship between the level of patient knowledge on warfarin therapy and the quality of oral anticoagulation: a systematic review and meta-analysis. PLoS One 2023;18:e0289836. https://doi.org/10.1371/journal.pone.0289836 831. Marx N, Federici M, Schütt K, Muller-Wieland D, Ajjan RA, Antunes MJ, et al. 2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes. Eur Heart J 2023;44:4043–140. https://doi.org/10.1093/eurheartj/ehad192 832. Meurin P, Tabet JY, Weber H, Renaud N, Ben Driss A. Low-molecular-weight heparin as a bridging anticoagulant early after mechanical heart valve replacement. Circulation 2006;113:564–9. https://doi.org/10.1161/circulationaha.105.575571 833. Ferreira I, Dos L, Tornos P, Nicolau I, Permanyer-Miralda G, Soler-Soler J. Experience with enoxaparin in patients with mechanical heart valves who must withhold acenocumarol. Heart 2003;89:527–30. https://doi.org/10.1136/heart.89.5.527 834. Caldeira D, David C, Santos AT, Costa J, Pinto FJ, Ferreira JJ. Efficacy and safety of low molecular weight heparin in patients with mechanical heart valves: systematic review and meta-analysis. J Thromb Haemost 2014;12:650–9. https://doi.org/10.1111/jth. 12544 835. Pengo V, Palareti G, Cucchini U, Molinatti M, Del Bono R, Baudo F, et al. Low-intensity oral anticoagulant plus low-dose aspirin during the first six months versus standard-intensity oral anticoagulant therapy after mechanical heart valve replacement: a pilot study of low-intensity warfarin and aspirin in cardiac prostheses (LIWACAP). Clin Appl Thromb Hemost 2007;13:241–8. https://doi.org/10.1177/ 1076029607302544 836. Meschengieser SS, Fondevila CG, Frontroth J, Santarelli MT, Lazzari MA. Low-intensity oral anticoagulation plus low-dose aspirin versus high-intensity oral anticoagulation alone: a randomized trial in patients with mechanical prosthetic heart valves. J Thorac Cardiovasc Surg 1997;113:910–6. https://doi.org/10.1016/s0022- 5223(97)70264-2 837. Puskas J, Gerdisch M, Nichols D, Quinn R, Anderson C, Rhenman B, et al. Reduced anticoagulation after mechanical aortic valve replacement: interim results from the prospective randomized On-X valve anticoagulation clinical trial randomized Food and Drug Administration investigational device exemption trial. J Thorac Cardiovasc Surg 2014;147:1202–10; discussion 1210–1201. https://doi.org/10.1016/j.jtcvs.2014. 01.004 838. Hanigan S, Kong X, Haymart B, Kline-Rogers E, Kaatz S, Krol G, et al. Standard versus higher intensity anticoagulation for patients with mechanical aortic valve replacement and additional risk factors for thromboembolism. Am J Cardiol 2021;159:100–6. https:// doi.org/10.1016/j.amjcard.2021.08.023 839. Ray WA, Chung CP, Murray KT, Smalley WE, Daugherty JR, Dupont WD, et al. Association of proton pump inhibitors with reduced risk of warfarin-related serious upper gastrointestinal bleeding. Gastroenterology 2016;151:1105–12.e1110. https:// doi.org/10.1053/j.gastro.2016.08.054 840. Kurlander JE, Barnes GD, Fisher A, Gonzalez JJ, Helminski D, Saini SD, et al. Association of antisecretory drugs with upper gastrointestinal bleeding in patients using oral anticoagulants: a systematic review and meta-analysis. Am J Med 2022;135:1231–43.e1238. https://doi.org/10.1016/j.amjmed.2022.05.031 841. Crowther MA, Ageno W, Garcia D, Wang L, Witt DM, Clark NP, et al. Oral vitamin K versus placebo to correct excessive anticoagulation in patients receiving warfarin: a randomized trial. Ann Intern Med 2009;150:293–300. https://doi.org/10.7326/0003- 4819-150-5-200903030-00005 842. Khatib R, Ludwikowska M, Witt DM, Ansell J, Clark NP, Holbrook A, et al. Vitamin K for reversal of excessive vitamin K antagonist anticoagulation: a systematic review and meta-analysis. Blood Adv 2019;3:789–96. https://doi.org/10.1182/bloodadvances. 2018025163 843. Gunther KE, Conway G, Leibach L, Crowther MA. Low-dose oral vitamin K is safe and effective for outpatient management of patients with an INR>10. Thromb Res 2004; 113:205–9. https://doi.org/10.1016/j.thromres.2004.03.004 844. Schulman S, Kearon C, Subcommittee on Control of Anticoagulation of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost 2005;3:692–4. https:// doi.org/10.1111/j.1538-7836.2005.01204.x 845. Brekelmans MPA, van Ginkel K, Daams JG, Hutten BA, Middeldorp S, Coppens M. Benefits and harms of 4-factor prothrombin complex concentrate for reversal of vitamin K antagonist associated bleeding: a systematic review and meta-analysis. J Thromb Thrombolysis 2017;44:118–29. https://doi.org/10.1007/s11239-017-1506-0 846. Chai-Adisaksopha C, Hillis C, Siegal DM, Movilla R, Heddle N, Iorio A, et al. Prothrombin complex concentrates versus fresh frozen plasma for warfarin reversal. A systematic review and meta-analysis. Thromb Haemost 2016;116:879–90. https://doi. org/10.1160/TH16-04-0266 847. Hood C, Goldstein JN, Milling TJ, Refaai MA, Bajcic P, Goldstein B, et al. INR and vitamin K-dependent factor levels after vitamin K antagonist reversal with 4F-PCC or plasma. Blood Adv 2023;7:2206–13. https://doi.org/10.1182/bloodadvances.2022009015 848. Sarode R, Milling TJJ, Refaai MA, Mangione A, Schneider A, Durn BL, et al. Efficacy and safety of a 4-factor prothrombin complex concentrate in patients on vitamin K antagonists presenting with major bleeding: a randomized, plasma-controlled, phase IIIb study. Circulation 2013;128:1234–43. https://doi.org/10.1161/CIRCULATIONAHA. 113.002283 849. Erdoes G, Koster A, Ortmann E, Meesters MI, Bolliger D, Baryshnikova E, et al. A European consensus statement on the use of four-factor prothrombin complex concentrate for cardiac and non-cardiac surgical patients. Anaesthesia 2021;76:381–92. https://doi.org/10.1111/anae.15181 850. Eichinger S. Reversing vitamin K antagonists: making the old new again. Hematology Am Soc Hematol Educ Program 2016;2016:605–11. https://doi.org/10.1182/asheducation- 2016.1.605 851. Birnie DH, Healey JS, Wells GA, Verma A, Tang AS, Krahn AD, et al. Pacemaker or defibrillator surgery without interruption of anticoagulation. N Engl J Med 2013;368: 2084–93. https://doi.org/10.1056/NEJMoa1302946 852. Di Biase L, Burkhardt JD, Santangeli P, Mohanty P, Sanchez JE, Horton R, et al. Periprocedural stroke and bleeding complications in patients undergoing catheter ablation of atrial fibrillation with different anticoagulation management: results from the Role of Coumadin in Preventing Thromboembolism in Atrial Fibrillation (AF) Patients Undergoing Catheter Ablation (COMPARE) randomized trial. Circulation 2014;129: 2638–44. https://doi.org/10.1161/CIRCULATIONAHA.113.006426 853. Engelen ET, Schutgens RE, Mauser-Bunschoten EP, van Es RJJ, van Galen KPM. Antifibrinolytic therapy for preventing oral bleeding in people on anticoagulants undergoing minor oral surgery or dental extractions. Cochrane Database Syst Rev 2018;7: CD012293. https://doi.org/10.1002/14651858.CD012293.pub2 854. Ghanbari H, Phard WS, Al-Ameri H, Latchamsetty R, Jongnarngsin K, Crawford T, et al. Meta-analysis of safety and efficacy of uninterrupted warfarin compared to heparin-based bridging therapy during implantation of cardiac rhythm devices. Am J Cardiol 2012;110:1482–8. https://doi.org/10.1016/j.amjcard.2012.06.057 855. Makuloluwa AK, Tiew S, Briggs M. Peri-operative management of ophthalmic patients on anti-thrombotic agents: a literature review. Eye (Lond) 2019;33:1044–59. https:// doi.org/10.1038/s41433-019-0382-6 856. Nagata N, Yasunaga H, Matsui H, Fushimi K, Watanabe K, Akiyama J, et al. Therapeutic endoscopy-related GI bleeding and thromboembolic events in patients using warfarin or direct oral anticoagulants: results from a large nationwide database analysis. Gut 2018;67:1805–12. https://doi.org/10.1136/gutjnl-2017-313999 Downloaded from academic.oup.com/eurheartj/article/46/44/4635/8234488 by guest on 07 October 2026